These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34108576)

  • 21. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone.
    Beermann KJ; Ellis MJ; Sudan DL; Harris MT
    Clin Transplant; 2014 Jul; 28(7):762-7. PubMed ID: 24754564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
    Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
    Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
    Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
    Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of serum bilirubin levels on kidney transplant outcomes.
    Lee J; Kim EJ; Lee JG; Kim BS; Huh KH; Kim MS; Kim SI; Kim YS; Joo DJ
    Sci Rep; 2021 Mar; 11(1):6889. PubMed ID: 33767325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes.
    Mendoza Rojas A; Hesselink DA; van Besouw NM; Dieterich M; de Kuiper R; Baan CC; van Gelder T
    Ther Drug Monit; 2022 Jun; 44(3):369-376. PubMed ID: 35394988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of two different antithymocyte globulins used in induction therapy in kidney transplant recipients: A single-center experience.
    Styrc B; Sobolewski M; Chudek J; Kolonko A; Więcek A
    Clin Transplant; 2019 Oct; 33(10):e13680. PubMed ID: 31365162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation.
    Xie W; Fan S; Liu R; Yan W; Su C; Zheng K; Wang X; Wang Z
    Transplant Rev (Orlando); 2024 Jul; 38(3):100842. PubMed ID: 38537484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High tacrolimus intra-patient variability is associated with graft rejection, and
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
    World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study.
    Alkadi MM; Kim J; Aull MJ; Schwartz JE; Lee JR; Watkins A; Lee JB; Dadhania DM; Seshan SV; Serur D; Kapur S; Suthanthiran M; Hartono C; Muthukumar T
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28921709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection.
    Sablik KA; Clahsen-van Groningen MC; Hesselink DA; van Gelder T; Betjes MGH
    PLoS One; 2018; 13(5):e0196552. PubMed ID: 29746495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
    Shuker N; Bouamar R; van Schaik RH; Clahsen-van Groningen MC; Damman J; Baan CC; van de Wetering J; Rowshani AT; Weimar W; van Gelder T; Hesselink DA
    Am J Transplant; 2016 Jul; 16(7):2085-96. PubMed ID: 26714287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
    Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients.
    Gokoel SRM; Zwart TC; Moes DJAR; van der Boog PJM; de Fijter JW
    Ther Drug Monit; 2020 Oct; 42(5):702-709. PubMed ID: 32941396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of pretransplant midodrine use on outcomes after kidney transplantation.
    Pottebaum AA; Hagopian JC; Brennan DC; Gharabagi A; Horwedel TA
    Clin Transplant; 2018 Sep; 32(9):e13366. PubMed ID: 30076650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
    Abu Bakar K; Mohamad NA; Hodi Z; McCulloch T; Williams A; Christian M; Key T; Kim JJ
    Pediatr Nephrol; 2019 Dec; 34(12):2557-2562. PubMed ID: 31520127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation.
    van der Veer MAA; Nangrahary N; Hesselink DA; Erler NS; Metselaar HJ; van Gelder T; Darwish Murad S
    Transplantation; 2019 Nov; 103(11):2329-2337. PubMed ID: 30801539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
    Vondrak K; Parisi F; Dhawan A; Grenda R; Webb NJA; Marks SD; Debray D; Holt RCL; Lachaux A; Kelly D; Kazeem G; Undre N
    Clin Transplant; 2019 Oct; 33(10):e13698. PubMed ID: 31436896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.